The following is a summary of the Viemed Healthcare, Inc. (VMD) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Viemed reported Q4 2023 net revenue of $50.7 million, a 35% increase from $37.5 million in Q4 2022, and FY2023 revenues of $183 million, a 32% rise year-over-year.

• Gross and EBITDA margins for Q4 2023 were 63.3% and 25.3% respectively, with amounts totaling $32.1 million and $12.8 million.

• The company saw a record EBITDA for 2023 at $43.1 million, marking the 7th consecutive year of positive net income.

• Free cash flow for Q4 2023 was $5.4 million, with an annual total of over $19 million.

• Q4 SG&A costs were $23.9 million, raising from $17.2 million in Q4 2022, yet the G&A costs as a percentage of revenue declined from 49% in 2022 to 48% in 2023.

Business Progress:

• Viemed's service extension, highlighted by the acquisition of HMP, increased the total rental patient count by 85% YoY, and the resupply patient count by 205%.

• The company made strides in restructuring and expanding its sales team, contributing to growth.

• They launched Engage Care Manager, a proprietary clinical management technology, which has led to enhanced patient satisfaction and new contracts.

• The transactional revenue of the company is approaching double digits, in line with its revenue diversification strategy.

• Viemed successfully expanded geographically, adding product offerings and diversifying its payer mix.

• For 2024, the company plans to continue investing in improving customer experience and aims to grow revenues at a faster rate than expenses, while also continuing to explore strategic partnerships and acquisitions.

More details: Viemed Healthcare IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.